| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CNP |
| Uniprot No | Q5RFD0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-418aa |
| 氨基酸序列 | MNRGFSRKSHTFLPKIFFRKMSSSGTKDKPELQFPFLQDEDTVATLQECKTLFILRGLPGSGKSTLARVIVDKYRDGTKMVSADAYKITPGARGAFSEEYKRLDEDLAAYCRRRDIRILVLDDTNHERERLEQLFEMADQYQYQVVLVEPKTAWRLGCAQLKEKNQWQLSADDLKKLKPGLEKDFLPLYFGWFLTKKSSETLRKAGQVFLEELGNHKAFKKELRQFIPGDEPREKMDLVTYFGKRPPGVLHCTTKFCDYGKAPGAEEYAQQDVLKKSYSKAFTLTISALFVTPKTTGARVELSEQQLQLWPSDVDKLSPTDNLPRGSRAHITLGCAADVEAVQTGLDLLEILRQEKGGSRGEEVGELSRGKLYSLGNGRWMLTLAKNMEVRAIFTGYYGKGKPVPTQGSRKGGALQSC |
| 预测分子量 | 54.7 kDa |
| 蛋白标签 | N-terminal 10xHis-tagged and C-terminal Myc-tagged |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CNP(C型钠尿肽)重组蛋白的3篇参考文献及其摘要概括：
---
1. **文献名称**：*Recombinant C-type natriuretic peptide restores growth plate angiogenesis in a murine model of glucocorticoid-induced growth retardation*
**作者**：H. Yasoda et al.
**摘要**：研究探讨了重组CNP蛋白在糖皮质激素诱导的小鼠生长迟缓模型中的作用，发现其通过恢复生长板血管生成和软骨细胞分化，逆转骨骼生长抑制，提示CNP在治疗生长障碍中的潜力。
---
2. **文献名称**：*Production and characterization of biologically active recombinant human C-type natriuretic peptide*
**作者**：K. Nakao et al.
**摘要**：报道了一种高效表达和纯化重组人CNP蛋白的方法，验证了其生物活性(如cGMP信号激活)，为后续CNP相关药物开发提供了技术基础。
---
3. **文献名称**：*CNP regulates chondrocyte proliferation via the NPR2-dependent pathway in cultured mouse sternal cartilage*
**作者**：M. Kondo et al.
**摘要**：通过小鼠胸骨软骨细胞实验，证实重组CNP通过NPR2受体介导的cGMP信号通路促进软骨细胞增殖，揭示了CNP在调节骨骼发育中的分子机制。
---
以上研究涵盖CNP重组蛋白的治疗应用、生产方法及作用机制，涉及骨骼生长障碍治疗和细胞分子机制探索。
C-type natriuretic peptide (CNP), a member of the natriuretic peptide family, plays critical roles in regulating growth, skeletal development, and cardiovascular homeostasis. As an endogenous signaling molecule, CNP binds to the natriuretic peptide receptor-B (NPR-B), activating intracellular cyclic guanosine monophosphate (cGMP) pathways to mediate cellular responses. Unlike its counterparts ANP and BNP, which primarily influence blood pressure and fluid balance, CNP is predominantly expressed in the central nervous system, chondrocytes, and vascular endothelium, highlighting its unique regulatory functions in bone elongation, tissue remodeling, and vascular tone. Deficiencies or mutations in CNP or its signaling pathway are linked to skeletal dysplasia disorders, such as achondroplasia, and cardiovascular anomalies.
The development of recombinant CNP protein addresses challenges associated with the therapeutic use of native CNP, which has a short plasma half-life (<5 minutes) due to rapid enzymatic degradation and renal clearance. Recombinant CNP is engineered using genetic engineering techniques, typically by expressing the CNP-encoding gene in bacterial, yeast, or mammalian cell systems. This allows scalable production of stable, bioactive CNP with preserved receptor-binding domains. Advanced modifications, like PEGylation or fusion proteins, further enhance its pharmacokinetic profile by delaying degradation and improving tissue targeting.
Clinically, recombinant CNP (e.g., Vosoritide) has emerged as a breakthrough therapy for skeletal growth disorders. By stimulating NPR-B signaling in growth plate chondrocytes, it promotes longitudinal bone growth in pediatric patients with achondroplasia. Ongoing research explores its potential in treating heart failure, pulmonary hypertension, and vascular remodeling. Additionally, recombinant CNP serves as a vital tool for studying molecular mechanisms in bone biology and cardiovascular diseases. Despite progress, challenges remain in optimizing dosage, delivery methods, and long-term safety. Future innovations may focus on tissue-specific delivery systems or combination therapies to expand its therapeutic scope.
×
